TG Therapeutics, Inc. - TGTX STOCK NEWS

TG Therapeutics presented study designs for post-marketing studies of BRIUMVI® (ublituximab) at the 2024 Consortium of Multiple Sclerosis Centers annual meeting. The studies focus on evaluating BRIUMVI's presence in breast milk and its impact on pregnancy and infant outcomes. These presentations are now publicly available on the company's website.

TG Therapeutics (NASDAQ: TGTX) has announced the schedule for upcoming presentations regarding BRIUMVI® (ublituximab) at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, set to take place from May 29 to June 1 in Nashville, Tennessee.

The presentations will highlight post-marketing studies on BRIUMVI for patients with relapsing forms of multiple sclerosis (RMS). Key sessions include:

- 'A Post-Marketing Study Evaluating the Presence and Concentration of BRIUMVI in Breast Milk' scheduled for May 30, led by Dr. Riley Bove from UCSF.

- 'BRIUMVI Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI' also on May 30, led by Dr. Riley Bove from UCSF.

Abstracts are available online on the CMSC meeting website.

Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.

TG Therapeutics reported strong financial results for the first quarter of 2024 with BRIUMVI U.S. net revenue of $50.5 million, total revenue of $63.5 million, and updated yearly guidance to $270 to $290 million in BRIUMVI U.S. net revenue in 2024. The company is also making progress in clinical goals and advancing its pipeline. Recent highlights include the commercialization of BRIUMVI in the U.S. and Europe, obtaining additional patents, and entering into a global license agreement. Financially, the company saw significant growth in product revenue and net loss reduction.

TG Therapeutics, Inc. (NASDAQ: TGTX) will host a conference call on May 1, 2024, to discuss the first quarter financial results and the business outlook for 2024. The call will be led by Michael S. Weiss, Chairman and CEO. Participants can join via phone or webcast.

TG Therapeutics announces additional data presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting. The company presented two additional data presentations from the ULTIMATE I & II Phase 3 trials, showcasing positive results in patients with relapsing forms of multiple sclerosis. The data highlighted the significant reduction in radiological disease activity and improved disability outcomes associated with earlier initiation of Ublituximab treatment. TG Therapeutics remains committed to research and the multiple sclerosis community, with ongoing evaluation of data from the Phase 3 trials and plans to present additional exploratory data throughout the year.

TG Therapeutics, Inc. (NASDAQ: TGTX) has been awarded a national contract by the Department of Veterans Affairs for BRIUMVI as the preferred anti-CD20 therapy for patients with relapsing forms of multiple sclerosis. The contract, with a potential value of $186,776,520, signifies a significant milestone for the company in providing access to BRIUMVI to Veterans across the country.

TG Therapeutics presents data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at AAN 2024 Annual Meeting, showcasing positive results from Phase 3 trials.

Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.